Loading…
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $79M | $15M | $-65M | $14M | -51.9% | 13.1% | -750.2% |
| 2024 | $70M | $12M | $10M | $9M | 5.5% | 17.5% | -0.1% |
| 2023 | $60M | $13M | $10M | $18M | 5.9% | 10.5% | -20.2% |
| 2022 | $54M | $18M | $12M | $14M | 7.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 53.91 | 59.58 | 70.01 | 79.18 |
| Cost Of Revenue | 10.82 | 11.63 | 26.86 | 32.96 |
| Gross Profit | 43.08 | 47.95 | 43.15 | 46.22 |
| Operating Expense | 28.17 | 38.72 | 37.02 | 39.73 |
| Operating Income | 14.91 | 9.22 | 6.13 | 6.49 |
| EBITDA | 18.48 | 13.06 | 11.80 | 14.70 |
| EBIT | 14.91 | 9.22 | 6.13 | 6.49 |
| Pretax Income | 15.12 | 11.70 | 12.41 | -69.38 |
| Tax Provision | 2.63 | 1.73 | 2.46 | -4.66 |
| Net Income | 12.48 | 9.96 | 9.95 | -64.72 |
| Net Income Common Stockholders | 12.48 | 9.96 | 9.95 | -64.72 |
| Total Expenses | 38.99 | 50.35 | 63.88 | 72.69 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 0.72 | 4.13 | 4.38 | 0.72 |
| Research And Development | 3.21 | 4.50 | 5.75 | 6.88 |
| Selling General And Administration | 24.96 | 34.22 | 31.27 | 32.84 |
| Normalized EBITDA | 19 | 14.73 | 9.89 | 91.29 |
| Normalized Income | 12.91 | 11.38 | 8.43 | 6.74 |
| Basic EPS | 0.62 | 0.50 | 0.50 | -3.22 |
| Diluted EPS | 0.60 | 0.49 | 0.49 | -3.22 |
| Tax Effect Of Unusual Items | -0.09 | -0.25 | 0.38 | -5.13 |
| Tax Rate For Calcs | 0.17 | 0.15 | 0.20 | 0.07 |
| Total Unusual Items | -0.51 | -1.66 | 1.91 | -76.59 |
| Total Unusual Items Excluding Goodwill | -0.51 | -1.66 | 1.91 | -76.59 |
| Net Income From Continuing Operation Net Minority Interest | 12.48 | 9.96 | 9.95 | -64.72 |
| Reconciled Depreciation | 3.57 | 3.84 | 5.67 | 8.21 |
| Reconciled Cost Of Revenue | 10.82 | 11.63 | 26.86 | 32.96 |
| Net Interest Income | 0.72 | 4.13 | 4.38 | 0.72 |
| Net Income From Continuing And Discontinued Operation | 12.48 | 9.96 | 9.95 | -64.72 |
| Total Operating Income As Reported | 14.91 | 8.72 | 6.13 | -70.73 |
| Diluted Average Shares | 20.75 | 20.46 | 20.30 | 20.10 |
| Basic Average Shares | 20.20 | 20.07 | 19.99 | 20.10 |
| Diluted NI Availto Com Stockholders | 12.48 | 9.96 | 9.95 | -64.72 |
| Net Income Including Noncontrolling Interests | 12.48 | 9.96 | 9.95 | -64.72 |
| Net Income Continuous Operations | 12.48 | 9.96 | 9.95 | -64.72 |
| Other Income Expense | -0.51 | -1.66 | 1.91 | -76.59 |
| Special Income Charges | -0.28 | -1.19 | 1.64 | -76.60 |
| Gain On Sale Of Ppe | 0 | -0.01 | 0 | -0.02 |
| Write Off | 0 | 0.50 | 0 | 77.22 |
| Restructuring And Mergern Acquisition | 0.28 | 0.68 | -1.64 | -0.64 |
| Gain On Sale Of Security | -0.23 | -0.47 | 0.27 | 0.01 |
| Net Non Operating Interest Income Expense | 0.72 | 4.13 | 4.38 | 0.72 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.72 | 4.13 | 4.38 | 0.72 |
| Selling And Marketing Expense | 4.88 | 6.56 | 8.91 | 11.90 |
| General And Administrative Expense | 20.09 | 27.66 | 22.35 | 20.94 |
| Other Gand A | 20.09 | 27.66 | 22.35 | 20.94 |
| Operating Revenue | 53.91 | 59.58 | 70.01 | 79.18 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Simulations Plus, Inc.this co. | SLP | $283M | - | 2.11 | -51.9% | 17.29 |
| Rezolute, Inc. | RZLT | $299M | - | 2.53 | -45.9% | -1.89 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - |
| 1.00 |
| -28.9% |
| 0.09 |
| RxSight, Inc. | RXST | $282M | - | 1.02 | -14.1% | -1.42 |
| Foghorn Therapeutics Inc. | FHTX | $279M | - | -2.49 | 68.5% | -2.05 |
| Editas Medicine, Inc. | EDIT | $276M | - | 10.11 | -586.6% | -1.57 |
| Accendra Health, Inc. | ACH | $267M | - | -0.58 | 238.8% | 5.96 |
| Peer Median | - | 15.33 | 1.01 | -21.5% | -1.50 | |